Effect of Agaricus Blazei (Murrill) ss. Heinemann (Sun Mushroom)

UPECLIN HC FM Botucatu Unesp

Status: Completed

Conditions: Nutritional Status; Hepatitis C; Hepatitis, Viral, Human

Treatments: Dietary Supplement: Agaricus blazei (Murrill) ss. Heinemann (sun mushroom)

Study type: Interventional

Funder types: Other

Identifiers

NCT00564811

upeclin/HC/FMB-Unesp-03

Details and patient eligibility

About

The aim of the study was to verify the influence of Agaricus blazei (Murrill) ss. Heinemann (A. blazei) on the evolution of nutritional state and liver function in hepatitis C patients.

Full description

Ten patients were studied (5 - GI - not taking A. blazei - and 5 - G2 - taking A. blazei), from both sexes, with positive Anti-VHC and a healthy nutritional state, admitted into in the viral hepatitis ward. Diagnosis and treatment for hepatitis C concurred with the regulations of the Ministry of Health and nutritional evaluation was performed in 3 moments according to anthropometrical, bioimpedance, biochemical and dietary standards, with duration of 6 months. The consumption of A. blazei (10g/day) in dehydrated powder was concomitant with antiviral therapy (conventional or pegylated interferon associated with ribavirin) with duration of 5 months.

Enrollment: 10 patients

Sex: All

Ages: 24 to 70 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• To have been informed and signed adequately the free and clarified assent
• Initiating the anti-viral treatment (interferon or pegylated interferon associate the ribavirin)
• Age: 24-70 years
• Gender :both the gender
• Race : all races
• To present serology positive to the anti-VHC ELISA
• To present genotype type 1,2,or 3
• Body mass index- >18,5 e < 35kg /m2
• Conditions full to the ORAL ingestion

Exclusion criteria

• Don't agree to the project or don't have signed the term of clarified free assent
• Restriction for oral ingestion
• The existence of surface of antigen of the hepatitis B virus(Ag HBs)
• The existence of antibody for the human immunodeficiency virus
• To be enclosed in another project of research or form of treatment
• Pregnant women
• Suckles
• Cirrhosis
• Patients with hepatitis auto-imune.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Single Group Assignment

Masking: None (Open label)

---

10 participants in 2 patient groups

G1

No Intervention group

G2

Experimental group

Treatment:

Dietary Supplement: Agaricus blazei (Murrill) ss. Heinemann (sun mushroom)